Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WTF?!? DUMP to 1.09? Scam or shorts?
I'd be very surprised if Dr Mike Chan was in any way involved with a scam or fraud.
Got to believe he is aware of NIVF's Press Release re: reverse merger...not a good look. 😼
$NIVF
Enovix Q1 2024 Earnings
👉️ $222M in dollar volume in an hour! 😺 $AGBA
👉️ $134 million in dollar volume in half an hour!!! $AGBA
$AGBA 4.29, ripping...
$AGBA +55% @ 3.64...NEWS/VOLUME... 🚀
$AGBA +43% @ 3.37...NEWS/VOLUME...
$AGBA BOOM +26% @ 2.95 on NEWS!
👉️ Dr Mike Chan will not fail... 😺 IMPOSSIBLE!!!
Dr Mike Chan is The Scientist ROCK STAR of ALLTIME! I plan to meet Dr Chan in 2025! I am a Shareholder in $NIVF!
🎵 In The Year Twenty O Twenty Five, If Man Is Still Alive 🎵
$NIVF
👉️ https://european-wellness.eu/ to reverse merge into https://newgenivf.com/
HelterAlert$
👉️ Dr Mike Chan will not fail... 😺 IMPOSSIBLE!!!
Dr Mike Chan is The Scientist ROCK STAR of ALLTIME! I plan to meet Dr Chan in 2025! I am a Shareholder in $NIVF!
🎵 In The Year Twenty O Twenty Five, If Man Is Still Alive 🎵
$NIVF
👉️ https://european-wellness.eu/ to reverse merge into https://newgenivf.com/
👉️ Dr Mike Chan cannot fail... 😺 It's just not possible.
Prof. Dato’ Sri Dr. Mike K.S. Chan is an author, educator and pioneer of Organotherapy, Cellular Therapy and Cell Membrane Therapy in Europe and Asia since the early 1980s. He founded and funded one of the world’s largest research on Bio-Molecular and Bio-Regenerative Medicine in Switzerland and Germany, with a global presence in almost eighty countries. He has conducted more than 1,000 lectures, seminars, and symposiums worldwide in the fields of organotherapy, cell therapies, age reversal, regenerative medicine, and stem-cell therapies.
In da house...Docctttooorrrrrr Miiikke Chaaaaan!
👉️ Dr Mike Chan cannot fail... 😺 It's just not possible.
Prof. Dato’ Sri Dr. Mike K.S. Chan is an author, educator and pioneer of Organotherapy, Cellular Therapy and Cell Membrane Therapy in Europe and Asia since the early 1980s. He founded and funded one of the world’s largest research on Bio-Molecular and Bio-Regenerative Medicine in Switzerland and Germany, with a global presence in almost eighty countries. He has conducted more than 1,000 lectures, seminars, and symposiums worldwide in the fields of organotherapy, cell therapies, age reversal, regenerative medicine, and stem-cell therapies.
In da house...Docctttooorrrrrr Miiikke Chaaaaan!
$NIVF
Running UP in overtime, GhosT, 1.91 could break 2, volume coming in...$NIVF
Who is this guy? 😺
https://european-wellness.eu/advisory/prof-dr-mike-chan/
$NIVF
InvestAmerica, here's the TARGET company for the reverse merger @ $5...
👉️ https://european-wellness.eu/about-us/
$NIVF
You're welcome 👉️ "Financially, with the acquisition of a profitable business and a US$30 million fundraising, we will be well-equipped to fund our future growth. Moreover, the issuance of additional ordinary shares will increase our market capitalization, ensuring higher trading liquidity. Finally, I believe that the deemed price of US$5 per share confirms that our current share price is undervalued compared to the long-term fair valuation of the company.”
NewGenIvf Signs Non-Binding Term Sheet for Potential Reverse Merger with European Wellness Investment Holdings
April 22 2024 - 9:00AM
NewGenIvf Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced the execution of a non-binding term sheet (the "Term Sheet") regarding a proposed reverse merger (the “Proposed Transaction”) with healthcare company European Wellness Investment Holdings Limited ("EWIHL").
Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen commented, “I am thrilled to announce the signing of a non-binding term sheet with EWIHL, a leading healthcare company. The proposed reverse merger will bolster our position in several key ways. Operationally, it will unlock significant synergies, expand our global reach, and help us to further improve fertility outcomes for our customers. Financially, with the acquisition of a profitable business and a US$30 million fundraising, we will be well-equipped to fund our future growth. Moreover, the issuance of additional ordinary shares will increase our market capitalization, ensuring higher trading liquidity. Finally, I believe that the deemed price of US$5 per share confirms that our current share price is undervalued compared to the long-term fair valuation of the company.”
The Proposed Transaction
Pursuant to the Term Sheet, it is proposed that NewGen issue 53,600,000 of its ordinary shares to the shareholder(s) of EWIHL or its associate (the “EWIHL Shareholders”) in exchange for 100% equity interest of EWIHL, at a deemed price per share of US$5, representing an aggregate amount of US$268,000,000. Simultaneously, it is proposed that NewGen raise US$30 million from public or private shareholders, in a form mutually acceptable to both NewGen and EWIHL.
Following stockholder approval of the Proposed Transaction, EWIHL Shareholders are expected to hold approximately 76.4% equity interest in NewGen. The Company expects to announce additional details regarding the Proposed Transaction when a definitive agreement is executed. The completion of the Proposed Transaction is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement, obtaining adequate financing, satisfaction of the conditions negotiated therein, and approval of the Proposed Transaction by the board and stockholders, as and when applicable. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.
About NewGen
NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen Group and its management have over a decade of experience in the fertility industry. NewGen's clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen's website is not incorporated by reference into this press release, and you should not consider it a part of this press release.
About European Wellness Investment Holdings Limited
European Wellness Biomedical Group (EW Group) is an international multi-award-winning European group renowned for its pioneering developments in precursor stem cell therapeutics, immunomodulation, biological and synthetic peptides, nutraceuticals, cosmeceuticals and biological regenerative medicine. EW Group owns a growing network of over 30 clinics and 4 hospitals worldwide and has over 600 (supplements/injectables) exclusive trademark products.
https://ih.advfn.com/stock-market/NASDAQ/newgenivf-NIVF/stock-news/93692684/newgenivf-signs-non-binding-term-sheet-for-potenti
InvestAmerica 👉️ Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of April 3, 2024: 10,149,386 Class A ordinary shares and 8,319,988 warrants.
40.5 million traded so far today...we're on autopilot run-mode 😺
Got a reverse merger potentially (@ $5)... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174289800
$NIVF
$NIVF +71% @ 2.20....HUGE VOLUME...
Too LATE?!? $ISUN "rescinds" RS -95% @ .15...
"in the hundreds of millions"
$AGBA
— Deep Blue (@DeepBlueEquity) April 24, 2024
Clearly SEC filings reveal Triller is being funded heavily by billionaire Richard Tsai ( Tsai Ming Hsing ) in the hundreds of millions. Tsai companies Fubon Financial, Tag Holdings, Total Formation Inc. are backing Triller.
🟢🟢🟢😺🟢🟢🟢
$AGBA
4 today, 4/24/24...😸
Not that I'm aware of Zorro. Someone seems to have "heard" something triggering that buy volume surge to 2.84...
The NEWS I'd love to hear..."AGBA at the Direction of it's Largest Shareholder Opens Preliminary Discussions With TikTok Post USA Ban"...and who better to "transfer" TikTok America Operations to than this feller (Rich, Billionaire, Chinese/Taiwan, speaks Mandurin/Chinese, owns the vehicle 👉️ AGBA), etc, etc:
Over 2M shares, direct injection, no churn, pOpped her UP to 2.84...almost $6M...what's up? 😛
Surge of BUY VOLUME coming in 😺 $AGBA
$SHIM +90% @ 4.27 Hi in AH 😺
$SHIM +60% @ 3.60...running in AH 😺
3s! Go $AGBA! 🚀
$AGBA running HARD to 3+ @ 2.93! 😺
$AGBA running back Up and OVER 3, @ 2.84 now...
$AGBA running back UP +9% @ 2.72 😎
$SHIM +38% @ 3.11...just starting...😺
$NIVF moving UP again +116% @ 2.76...🚀
Merger going to $5...$NVIF news:
NewGenIvf Signs Non-Binding Term Sheet for Potential Reverse Merger with European Wellness Investment Holdings
April 22 2024 - 9:00AM
NewGenIvf Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced the execution of a non-binding term sheet (the "Term Sheet") regarding a proposed reverse merger (the “Proposed Transaction”) with healthcare company European Wellness Investment Holdings Limited ("EWIHL").
Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen commented, “I am thrilled to announce the signing of a non-binding term sheet with EWIHL, a leading healthcare company. The proposed reverse merger will bolster our position in several key ways. Operationally, it will unlock significant synergies, expand our global reach, and help us to further improve fertility outcomes for our customers. Financially, with the acquisition of a profitable business and a US$30 million fundraising, we will be well-equipped to fund our future growth. Moreover, the issuance of additional ordinary shares will increase our market capitalization, ensuring higher trading liquidity. Finally, I believe that the deemed price of US$5 per share confirms that our current share price is undervalued compared to the long-term fair valuation of the company.”
The Proposed Transaction
Pursuant to the Term Sheet, it is proposed that NewGen issue 53,600,000 of its ordinary shares to the shareholder(s) of EWIHL or its associate (the “EWIHL Shareholders”) in exchange for 100% equity interest of EWIHL, at a deemed price per share of US$5, representing an aggregate amount of US$268,000,000. Simultaneously, it is proposed that NewGen raise US$30 million from public or private shareholders, in a form mutually acceptable to both NewGen and EWIHL.
Following stockholder approval of the Proposed Transaction, EWIHL Shareholders are expected to hold approximately 76.4% equity interest in NewGen. The Company expects to announce additional details regarding the Proposed Transaction when a definitive agreement is executed. The completion of the Proposed Transaction is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement, obtaining adequate financing, satisfaction of the conditions negotiated therein, and approval of the Proposed Transaction by the board and stockholders, as and when applicable. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.
About NewGen
NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen Group and its management have over a decade of experience in the fertility industry. NewGen's clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen's website is not incorporated by reference into this press release, and you should not consider it a part of this press release.
About European Wellness Investment Holdings Limited
European Wellness Biomedical Group (EW Group) is an international multi-award-winning European group renowned for its pioneering developments in precursor stem cell therapeutics, immunomodulation, biological and synthetic peptides, nutraceuticals, cosmeceuticals and biological regenerative medicine. EW Group owns a growing network of over 30 clinics and 4 hospitals worldwide and has over 600 (supplements/injectables) exclusive trademark products.
$NVIF
$NVIF +130% @ 2.95! BOOM! 😸
+114% @ 2.73! Running HARD on volume/news! $NIVF